GlassScriptPhysician profile
Joel W Ferree
NPI 1245238211
$2,936.42
in general payments reported to CMS, 2019-2025
24 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $223 · 2021: $375 · 2022: $474 · 2023: $397 · 2024: $400 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $481.57 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $443.08 | 2019-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $346.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $322.44 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $267.85 | 2019-2025 | Camzyos |
| Philips North America LLC | $172.95 | 2022-2025 | (5091) Amb Mon & Diag Und, Extended Holter |
| Abiomed | $163.29 | 2019 | |
| Pfizer INC. | $82.85 | 2022-2024 | |
| Daiichi Sankyo INC. | $74.18 | 2019-2023 | Injectafer |
| Boston Scientific Corporation | $63.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.12 | 2019-2022 | |
| Vital Connect, INC | $51.21 | 2024-2025 | Vitalpatch Rtm |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.88 | 2019-2022 | |
| Medtronic, INC. | $48.58 | 2021-2023 | Linq II |
| Medtronic Vascular, INC. | $41.40 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.50 | 2025 | |
| Cardiva Medical, INC. | $39.16 | 2019 | |
| Braemar Manufacturing, LLC | $34.71 | 2019 | |
| Esperion Therapeutics, INC. | $34.06 | 2021-2023 | Nexletol |
| Abbott Laboratories | $33.72 | 2022 | |
| Kestra Medical Technology Services, INC. | $27.96 | 2025 | Assure Wcd |
| Cvrx, INC. | $24.33 | 2023 | Barostim Neo System |
| Novo Nordisk INC | $19.50 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $14.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Ferree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.